单克隆抗体靶向治疗儿童严重支气管哮喘的研究现状  

Research status of monoclonal antibody targeted therapy in children with severe bronchial asthma

作　　者：李竹青 王晓红[2] Li Zhuqing;Wang Xiaohong(Shanxi Medical University,Taiyuan 030001,China;Department of Pediatrics,the First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学,太原030001 [2]山西医科大学第一医院儿科,太原030001

出　　处：《中国综合临床》2021年第4期381-384,共4页Clinical Medicine of China

摘　　要：单克隆抗体是儿童严重哮喘的一种新型治疗方法,主要通过选择性作用于哮喘炎症级联反应中的特定细胞因子或途径,阻断炎症反应,从而降低哮喘急性发作次数、减少药物用量,并且改善肺功能。其主要不良反应包括注射部位反应及上呼吸道感染等。目前可用于儿童的单克隆抗体包括Omalizumab、Mepolizumab、Benralizumab、Reslizumab和Dupilumab,虽然单克隆抗体用于儿童哮喘疗效明显,但其长期影响及安全性仍需大量临床研究进一步证实。Monoclonal antibody is a new treatment for severe asthma in children.It can selectively act on specific cytokines or pathways in the inflammatory cascade of asthma to block the inflammatory reaction,so as to reduce the number of acute attacks of asthma,reduce the dosage of drugs,and improve lung function.The main adverse reactions included injection site reaction and upper respiratory tract infection.At present,monoclonal antibodies for children include Omalizumab,Mepolizumab,Benralizumab,Reslizumab and Dupilumab.Although the efficacy of monoclonal antibody in children with asthma is obvious,its long-term effect and safety still need to be further confirmed by a large number of clinical studies.

关 键 词：单克隆抗体 OMALIZUMAB MEPOLIZUMAB Benralizumab Reslizumab Dupilumab 儿童哮喘 

分 类 号：R725.6[医药卫生—儿科]